NCT04058145 2020-09-07
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
Massachusetts General Hospital
Phase 2 Withdrawn
Massachusetts General Hospital
Jonsson Comprehensive Cancer Center
University of Maryland, Baltimore
Fred Hutchinson Cancer Center
Sanofi